[Effects of emoxipine on lipid peroxidation in patients with chronic heart failure].
Lipid peroxidation (LPO) was studied in 90 patients with chronic heart failure (CHF) in relation to the disease stage. The patients with various CHF showed increased LPO and decreased antioxidative function. Impaired LPO was more pronounced in patients with Stage II CHF. To correct LPO processes, emoxipine, a new synthetic antioxidant, was used in 48 patients. The agent in a dose of 40 mg/day was ascertained to have a regulatory effect on the oxidative-antioxidative system in patients with heart failure. A more profound effect was observed in patients with Stage I patients. The main mechanism of the antioxidative action of emoxipine in CHF was to enhance glutathione reductase and glutathione peroxidase and to lower the level on dienic conjugates in patients with Stage IIB CHF.
Rudyk
B I
BI
Sabadyshin
R A
RA
D000328:Adult; D000975:Antioxidants / Q000627:therapeutic use*; D005260:Female; D006333:Heart Failure / Q000188:drug therapy* / Q000378:metabolism; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D010847:Picolines / Q000627:therapeutic use*
D000975:Antioxidants; D010847:Picolines; C009820:6-methyl-2-ethyl-3-hydroxypyridine
Vliianie émoksipina na sostoianie perekisnogo okisleniia lipidov u bol'nykh s khronicheskoĭ serdechnoĭ nedostatochnost'iu.